The Cancer Research Machine Trump Is Gutting Just Delivered a Big Breakthrough

Researchers at Harvard announced groundbreaking results for pancreatic cancer treatment during the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on May 31, 2026. The drug daraxonrasib extended survival by 13.2 months on average for patients who had already undergone chemotherapy, compared to 6.7 months with standard secondary chemo treatments. The revelation sparked standing ovations from oncologists, marking a rare moment of excitement in pancreatic cancer research, which has long resisted treatment advancements. Pancreatic cancer remains the third-deadliest cancer in the U.S., claiming over 50,000 American lives annually. Daraxonrasib is not a cure, but its effectiveness offers a critical breakthrough for patients in advanced stages of the disease. Side effects include severe rashes and gastrointestinal issues, though they are less severe than those from additional chemotherapy. Former Nebraska Senator Ben Sasse, who has been using the drug in clinical trials, has spoken publicly about its impact and challenges. The drug’s development reflects years of scientific effort, but critics argue that recent policy shifts under the Trump administration—including cuts to cancer research funding—could hinder future discoveries. While daraxonrasib provides immediate hope, experts emphasize the need for sustained investment to address pancreatic cancer’s high mortality rate and improve long-term outcomes. Daraxonrasib’s success was widely reported across major news outlets, including The Washington Post, CNN, and STAT News, underscoring its potential to reshape treatment strategies. However, the drug’s approval and accessibility depend on regulatory approval and continued research funding, which remains uncertain amid broader debates over healthcare priorities. The clinical trial results were presented by Harvard researcher Brian Wolpin, who delivered the findings in a measured tone that contrasted with the emotional response from the audience. The reaction highlighted the urgency of pancreatic cancer research, where progress has historically been slow compared to other cancers like breast or lung cancer. While daraxonrasib offers a promising step forward, its long-term impact hinges on broader support for medical research and policy decisions that prioritize patient outcomes over budget cuts.